Sartorius Ag · XETR:SRT
Sartorius — Q3 2025 Earnings Presentation
18 slides from Sartorius's earnings presentation, Oct 16, 2025
Slide 1: Simplifying Progress – Investor Conference Call 9M 2025 Results
Simplifying Progress Investor Conference Call 9M 2025 Results Michael Grosse, Florian Funck, René Fáber Sartorius | Sartorius Stedim Biotech October 16, 2025
Slide 2: Sartorius continues delivering significant profitable growth
Sartorius Group Sartorius continues delivering significant profitable growth Robust sales growth of 7.5% cc; significant ul EBITDA margin expansion to 29.7% despite FX headwinds Bioprocess Solutions: Continued strong momentum in consumables business; equipment business soft but stabilizing Lab
Slide 3: Agenda
Agenda Sartorius Group 9M 2025 results | FY 2025 outlook Sartorius Stedim Biotech Group 9M 2025 results | FY 2025 outlook Questions & Answers 3
Slide 4: Robust topline performance; continued strong margin improvement
Sartorius Group Robust topline performance; continued strong margin improvement Sartorius Group 9M 2024 9M 2025 in % in % cc 1 in millions of € unless otherwise specified Sales revenue 2,474 2,611 +5.5 +7.5 Underlying EBITDA2 686 774 +12.8 Underlying EBITDA2 margin in % 27.7 29.7 +2.0pp Underlying E
Slide 5: All regions contributing to positive development
Sartorius Group All regions contributing to positive development EMEA Americas Asia | Pacific Sales by region Sales | € in millions Sales | € in millions Sales | € in millions in % +6.3% +8.2% +8.7% EMEA Americas 1,020 1,084 925 ~42% ~35% 879 574 602 €2,611m Asia | Pacific 9M 2024 9M 2025 9M 2024 9M
Slide 6: Bioprocess Solutions: Significant revenue growth and margin expansion
Sartorius Group Bioprocess Solutions: Significant revenue growth and margin expansion Sales revenue +9.9% cc Ul EBITDA & margin € in millions +7.8% € in millions +17.3% 2,115 1,962 800 667 55 700 568 50 600 45 500 40 400 28.9 31.5 35 300 30 200 25 100 20 0 15 9M 2024 9M 2025 9M 2024 9M 2025 Double
Slide 7: Lab Products & Services: Resilient performance in challenging environment
Sartorius Group Lab Products & Services: Resilient performance in challenging environment Sales revenue Ul EBITDA & margin -1.3% cc € in millions € in millions -3.2% -9.1% 511 495 118 108 23.2 21.7 9M 2024 9M 2025 9M 2024 9M 2025 Significant growth of recurring business with lab consumables and se
Slide 8: Substantial increase in net profit and solid cash flow generation
Sartorius Group Substantial increase in net profit and solid cash flow generation Sartorius Group 9M 2024 9M 2025 in % in millions of € unless otherwise specified Underlying net profit1,2 208 244 +17.0 Operating cash flow on solid level; growth-driven Reported net profit2 75 125 +66.0 increase in
Slide 9: Deleveraging as planned; commitment to investment-grade rating
Sartorius Group Deleveraging as planned; commitment to investment-grade rating Key financial indicators Net debt and net debt to underlying EBITDA 6.0 Sartorius Group Dec. 31, Sep. 30, 5,000 5.0 in millions of € unless otherwise specified 2024 2025 4,000 4.0 Equity ratio in % 38.6 39.7 3,000 3.0 2,0
Slide 10: Specified FY 2025 guidance on the back of significant profitable growth
Sartorius Group Specified FY 2025 guidance on the back of significant profitable growth Guidance 2025 Sales revenue growth1 Underlying EBITDA margin New guidance Initial guidance2 New guidance Initial guidance2 Sartorius Group + ~7% + ~6% (+/-2pp) Slightly above 29.5% ~29% to ~30% Bioprocess Solutio
Slide 11: Agenda
Agenda Sartorius Group 9M 2025 results | FY 2025 outlook Sartorius Stedim Biotech Group 9M 2025 results | FY 2025 outlook Questions & Answers 11
Slide 12: Considerable topline performance; continued strong margin improvement
Sartorius Stedim Biotech Group Considerable topline performance; continued strong margin improvement Sartorius Stedim Biotech Group 9M 2024 9M 2025 in % in % cc 1 in millions of € unless otherwise specified Sales revenue 2,029 2,195 +8.2 +10.2 Underlying EBITDA2 565 683 +21.0 Underlying EBITDA2 marg
Slide 13: Significant growth in all regions
Sartorius Stedim Biotech Group Significant growth in all regions EMEA Americas Asia | Pacific Sales by region Sales | € in millions Sales | € in millions Sales | € in millions in % +8.4% +11.8% +11.2% EMEA Americas ~42% ~36% 782 460 492 850 921 719 €2,195m Asia | Pacific 9M 2024 9M 2025 9M 2024 9M 2
Slide 14: Substantial increase in net profit and solid cash flow generation
Sartorius Stedim Biotech Group Substantial increase in net profit and solid cash flow generation Sartorius Stedim Biotech Group 9M 2024 9M 2025 in % in millions of € unless otherwise specified Underlying net profit1,2 238 320 +34.3 Operating cash flow on solid level; growth-driven Reported net pro
Slide 15: Deleveraging on track
Sartorius Stedim Biotech Group Deleveraging on track Key financial indicators Net debt and net debt to underlying EBITDA 4,000 6.0 Sartorius Stedim Biotech Dec. 31, Sept. 30, 5.0 3,000 Group 2024 2025 4.0 in millions of € unless otherwise specified 2,000 3.0 Equity ratio in % 48.7 51.7 2.0 1,000 1.0
Slide 16: Specified FY 2025 guidance at upper-end of initial forecast range
Sartorius Stedim Biotech Group Specified FY 2025 guidance at upper-end of initial forecast range Guidance 2025 Sales revenue growth1 Underlying EBITDA margin New FY 2025 guidance Initial guidance2 New FY 2025 guidance Initial guidance2 Sartorius Stedim + ~9% + ~7% (+/-2pp) ~31% ~30% to ~31% Biotech
Slide 17: Questions & Answers
17 Questions & Answers YRTORILS
Slide 18: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha